James Smith, MD
Hematology & Oncology · Florence, SCNPI 1972543114
Payments from drug & device makers
Across 99 payments — averaging $25.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$262
- Astellas Pharma US Inc$244
- Johnson & Johnson$235
- Bristol Myers Squibb$164
- E.r. Squibb & Sons, L.L.C.$162
- Amgen$142
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,17285%
- Education$37215%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $262 |
| Astellas Pharma US Inc | 6 | $244 |
| Johnson & Johnson | 7 | $235 |
| Bristol Myers Squibb | 9 | $164 |
| E.r. Squibb & Sons, L.L.C. | 7 | $162 |
| Amgen | 5 | $142 |
| AbbVie | 3 | $122 |
| Stryker | 3 | $118 |
| Galvanize Therapeutics, Inc | 1 | $117 |
| Seagen Inc. | 2 | $116 |
| Merck | 5 | $111 |
| Boehringer Ingelheim | 5 | $87 |
| Pfizer | 4 | $84 |
| Genentech USA, Inc. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| AstraZeneca | 2 | $40 |
| Rigel Pharmaceuticals, Inc. | 2 | $40 |
| GSK | 2 | $39 |
| Gilead | 1 | $31 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Eisai Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Exelixis Inc. | 1 | $23 |
| Geron Corporation | 1 | $22 |
| Stemline Therapeutics Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Sanofi | 1 | $20 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Springworks Therapeutics, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Array Biopharma Inc | 1 | $17 |
| Adaptive Biotechnologies Corporation | 1 | $16 |
| Incyte Corporation | 1 | $16 |
| Abbott | 1 | $15 |
| Sobi, Inc | 1 | $15 |
| EMD Serono, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALIYA SYSTEM$117
How this compares
$2,544 in reported general payments places this provider in the 30th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 74 | $1,035,437 |
| RevlimidLenalidomide | 51 | $943,428 |
| Lenalidomide | 48 | $635,715 |
| TasignaNilotinib Hcl | 28 | $547,758 |
| LenvimaLenvatinib Mesylate | 17 | $405,708 |
| PomalystPomalidomide | 17 | $379,524 |
| PromactaEltrombopag Olamine | 25 | $318,652 |
| Abiraterone Acetate | 56 | $275,797 |
| KisqaliRibociclib Succinate | 15 | $255,584 |
| CalquenceAcalabrutinib Maleate | 12 | $184,841 |
| VenclextaVenetoclax | 15 | $125,428 |
| EliquisApixaban | 99 | $74,036 |
| Imatinib Mesylate | 18 | $22,500 |
| XareltoRivaroxaban | 18 | $21,199 |
| Enoxaparin Sodium | 23 | $11,748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna, Promacta, Kisqali | $262 | $1,121,99468 claims |
| Astellas Pharma US IncXtandi | $244 | $1,035,43774 claims |
| Bristol Myers SquibbRevlimid | $164 | $943,42851 claims |
| Eisai Inc.Lenvima | $24 | $405,70817 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $162 | $379,52417 claims |
| AstraZenecaCalquence | $40 | $184,84112 claims |
| AbbVieVenclexta | $122 | $125,42815 claims |
| PfizerEliquis | $84 | $74,03699 claims |
| Johnson & JohnsonXarelto | $235 | $21,19918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Florence
- Rajesh BajajFlorence$126K
- Mark KeatonFlorence$26K
- Ki ChungSpartanburg$4.7M
- Stephen DyarGreenville$4.5M
- Suzanne FanningGreenville$3.9M
- Vikas DemblaSpartanburg$3.2M
- Robert StuartCharleston$2.9M
- Tondre BuckSpartanburg$2.1M
- William EdenfieldGreenville$1.7M
- Bhumika PatelGreenville$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.